Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 7/20 | 0.48 |
| ▸ | PRKDC | P78527 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505741 | 0.84 | SQOR (0.59) | MAPTALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL29131667 | 0.84 | SQOR (0.59) | MAPTALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL935340 | 0.81 | AURKA (0.48) | MAPTSMN1; SMN2ATRPRKDCKMT2A | |
| SCHEMBL27544429 | 0.80 | ATR (0.50) | ATRPRKDCATM | |
| SCHEMBL3459860 | 0.79 | ATR (0.46) | ATRPRKDCTLR9ATM | |
| SCHEMBL10305052 | 0.79 | ATR (0.50) | MAPTALDH1A1SQORATRPRKDC | |
| SCHEMBL12489014 | 0.77 | ATR (0.56) | SMN1; SMN2ATRPRKDCNPC1RAB9A | |
| SCHEMBL29519952 | 0.77 | ATR (0.56) | SMN1; SMN2ATRPRKDCNPC1RAB9A | |
| SCHEMBL6056998 | 0.77 | SQOR (0.51) | MAPTALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL2681285 | 0.77 | SMN1; SMN2 (0.51) | MAPTALDH1A1GLAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| EP-2099769-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| WO-2008073305-A1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458715-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051870-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | MAPT 520/4885ALDH1A1 3484/4885GLA 1730/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | MAPT 520/4885ALDH1A1 3484/4885GLA 1730/4885 |
| US-20050075346-A1 | Novel compounds | CCL11, CCL2, CCL5 | MAPT 3931/4885ALDH1A1 685/4885GLA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.